Cardiology Letters 2017, 26(4):223-227

Aktualizovaná liečba mitrálnej regurgitácie založenej na MitraClip

Ondrus T^1,2, Penicka M², Kotrc M³, Vanderheyden M², Bartunek J²

¹ Department of Internal Medicine and Cardiology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic

² Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium

³ Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic

Despite the evidence of unfavourable prognosis, around half of patients with severe MR are not referred for surgery due to high per-operative risk. MitraClip (Abbott Vascular-Structural Heart, Menlo Park, California, United States) implantation is an emerging percutaneous technique with edge-to-edge MV repair inspired by the Alfieri surgery. Favourable safety profile together with improvement of functional status and decrease of MR severity in high-surgical-risk patients have been demonstrated in randomized clinical trials and ''real-world'' registries for both primary and secondary MR. Our own data confirmed its safety and efficacy comparing to minimally invasive MV surgery in treatment of functional MR in population with severe systolic heart failure. In order to extend the information, we publish our work as a secondary publication in the journal Cardiology Letters. The primary publication was published in Cor et Vasa 2017, 59, 85-91

Uverejnené: April 1, 2017  Zobraziť citáciu